Bio-Technology is a growing company. But for more than four decades, scientists, researchers, and entrepreneurs working in this field have established themselves in the early stages of drug development. New developments and research from these companies have resulted in excellent treatments and innovative therapies that are changing the way we treat patients for a variety of devastating diseases, including:
• Hepatitis C – a chronic disease whose current treatment rate is more than 90%1;
• HIV/AIDS has changed from a death sentence to a permanent establishment2;
Advances in immunization have saved more than 730,000 children in the United States in the last 20 years3;
• Cancer deaths have fallen by 20% since their peak in 1991, mainly due to treatment.
Strong experience in crop technology can mean that both men and women work in the field. For them, plant technology is not just a job, it is a message and a call to solve the biggest problem of our time: developing the essence of life itself and using that knowledge to act compassionately and in the name of hope. . They are entrepreneurs. They are the ones who pose the threat. They are hardworking scientists in this situation of COVID.
Their passion and perseverance are the reasons why small companies produce nearly 70 percent of the company’s pharmaceutical pipeline.5 These companies are leading the next generation of innovations, including the major growth in genetic therapy, immunotherapy, and RNAi medicine. These innovations are poised to change medicine in the 21st century.
Most of the companies working on these innovations, as well as all of the manufacturing technologies, were small businesses that first made money. Its success in purchasing new treatments and therapies hinges on a key factor: the ability to attract large sums of money to support this powerful and high-risk business. These strengths, in turn, are based on a public legal situation that supports innovation and encourages such investments, including advances in scientific understanding; powerful intelligence (IP) and reliable systems for IP transfer, licensing and collaboration; a predictable effective management system review; and a clear payment system that updates new products and supports competition in the free market.